Sample list of current or past clients:
BioHealth Innovation, Inc. (BHI) — The central Maryland region has unmatched biohealth assets from iconic federal institutions, world-class universities, top-notch healthcare facilities, and global and emerging bioscience companies. However, we have yet to fully realize the return on investment from these assets. This is largely due to the lack of a cohesive strategy in moving ideas from labs to the market. While other regions with far less assets have proactively addressed this opportunity by creating innovation-driven economic development organizations and initiatives. It is time central Maryland started to close this gap, and it is BioHealth Innovation’s mission to complete. Learn more at www.biohealthinnovation.org.
Gliknik Inc. — Founded in 2007, Gliknik is a biotechnology company making new therapies for patients with cancer and autoimmune/inflammatory diseases. Its mission is to discover, develop and bring to market truly novel therapies. Its expertise is modulation of the immune system. Gliknik is based at the University of Maryland BioPark, Baltimore, Maryland. In 2009, Gliknik was named Maryland Best New Incubator Company of the Year. For more information, visit www.gliknik.com.
GlycoMimetics, Inc. — Founded in 2003, GlycoMimetics is developing small molecule drugs targeting unmet clinical needs in orphan disease indications. The company’s lead product, GMI-1070, is initially being developed for the treatment of vaso-occlusive crisis in sickle cell disease and has been granted Orphan Drug and Fast Track Status by the U.S. Food and Drug Administration. The company announced positive topline results from a Phase 2 trial with GMI-1070 in April 2013. For additional information, please visit the company’s web site: www.glycomimetics.com.
UM BioPark — The BioPark is a biomedical research park on the vibrant academic medical center campus of the University of Maryland, Baltimore (UMB). Its community of life science companies and academic research centers are commercializing new drugs, diagnostics and devices and advancing biomedical research. For more information, please visit, www.umbiopark.com.